erectile%20dysfunction
ERECTILE DYSFUNCTION

Erectile dysfunction is the inability to attain and maintain an erection enough to have satisfactory sexual performance for ≥3 months.

It is when the patient complains of partial erection that could not attain vaginal penetration.

Complete loss of penile rigidity is uncommon.

Initial penile erections can penetrate but early detumescence occurs without ejaculation.

Surgical Intervention

Penile Vascular Surgery

  • Arterial reconstructive surgery should be considered only in healthy men w/ recently acquired erectile dysfunction due to a focal arterial occlusion in the absence of a generalized vascular disease

Penile Drug Delivery (Implanted) Devices

  • May be tried before standard implants are used if erection is possible w/ pharmacological injection

Penile Implants

  • Considered final treatment for erectile dysfunction patients & should be reserved for patients who have failed other treatments
  • Irreversible & highly invasive
  • When performed by experienced surgeon has been associated w/ high rate of patient satisfaction
  • May have surgical complication & mechanical failure
  • Available classes of penile implants are inflatable (2- & 3- piece) & malleable devices
  • Surgical approaches include penoscrotal & infrapubic
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 2 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.